Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients – an overview

Eveline van de Stadt, Maqsood Yaqub, A. A. Jahangir, Harry Hendrikse, Idris Bahce

Research output: Contribution to journalReview articleAcademicpeer-review

2 Citations (Scopus)

Abstract

Non-small cell lung cancer (NSCLC) has one of the highest cancer-related mortality rates worldwide. In a subgroup of NSCLC, tumor growth is driven by epidermal growth factor receptors (EGFR) that harbor an activating mutation. These patients are best treated with EGFR tyrosine kinase inhibitors (EGFR TKI). Identifying the EGFR mutational status on a tumor biopsy or a liquid biopsy using tumor DNA sequencing techniques is the current approach to predict tumor response on EGFR TKI therapy. However, due to difficulty in reaching tumor sites, and varying inter- and intralesional tumor heterogeneity, biopsies are not always possible or representative of all tumor lesions, highlighting the need for alternative biomarkers that predict tumor response. Positron emission tomography (PET) studies using EGFR TKI-based tracers have shown that EGFR mutational status could be identified, and that tracer uptake could potentially be used as a biomarker for tumor response. However, despite their likely predictive and monitoring value, the EGFR TKI-PET biomarkers are not yet qualified to be used in the routine clinical practice. In this review, we will discuss the currently investigated EGFR-directed PET biomarkers, elaborate on the typical biomarker development process, and describe how the advances, challenges, and opportunities of EGFR PET biomarkers relate to this process on their way to qualification for routine clinical practice.
Original languageEnglish
Article number900450
JournalFrontiers in Oncology
Volume12
DOIs
Publication statusPublished - 12 Oct 2022

Keywords

  • EGFR TKI
  • NSCLC
  • PET/CT
  • molecular imaging
  • radiolabeled EGFR TKI

Cite this